Panel discussion

Molecular Partners

Date:April 23, 2024

Panel title

Radioligand Therapies – How Switzerland is enabling innovation in nuclear medicine

Panel summary

For over a decade, Swiss companies and scientists have been at the forefront of nuclear medicine. As the field of radiotherapeutics continues to grow, how will Switzerland continue to contribute and lead in this next era of innovation for cancer patients? Join us live as we discuss!

Speaker information


Ken Herrmann, Chair, Department of Nuclear Medicine, Universitätsmedizin Essen


Emanuele Ostuni, CEO, Artbio
Roger Schibli, Head of Center for Radiopharmaceutical Sciences, PSI
Jeevan Virk, RLT Therapeutic Area Strategy Head, Novartis
Daniel Steiner, SVP Research & Technology, Molecular Partners

Company profile

Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of a novel class of DARPin therapeutics for medical challenges that other drug modalities cannot readily address. DARPin therapeutics are a new class of custom-built protein drugs based on natural binding proteins that open new dimensions of multi-functionality and multi-target specificity in drug design. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main current focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies.